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Preceding the joint meeting of the 19th annual Diabetic Neuropathy Study Group of the Euro-
pean Association for the Study of Diabetes (NEURODIAB) and the 8th International Symposium
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to provide updates on classification, definitions, diagnostic criteria, and treatments of diabetic
peripheral neuropathies (DPNs), autonomic neuropathy, painful DPNs, and structural alter-
ations in DPNs.
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CLASSIFICATION AND
DEFINITION OF DIABETIC
NEUROPATHIES— The neuropa-
thies developing in patients with diabetes
are known to be heterogenous by their
symptoms, pattern of neurologic involve-
ment, course, risk covariates, pathologic
alterations, and underlying mechanisms
(1,2). Thomas (3) and Boulton et al. (4)
separated these into generalized and fo-
cal/multifocal varieties (e.g., multiple
mononeuropathy, lumbosacral, thoracic,
and cervical radiculoplexus neuropa-
thies) (3,4). It is known that similar pat-
terns of neuropathy occur in patients
without diabetes (2). Moreover, diabetic
patients can develop chronic inflamma-
tory demyelinating polyradiculopathy.
The evidence that generalized variet-
ies can be further classified into at least
two major subgroups seems compelling
(3,4). The typical DPN is a chronic, sym-
metrical, length-dependent sensorimotor
polyneuropathy (DSPN) and is thought to
be the most common variety (1). It devel-
ops on (or with) a background of long-
standing hyperglycemia, associated
metabolic derangements (increased
polyol flux, accumulation of advanced
glycation end products, oxidative stress,
and lipid alterations among other meta-
bolic abnormalities) and cardiovascular
risk factors (5–7). Alterations of mi-
crovessels, similar to those observed in di-
abetic retinopathy and nephropathy,
appear to be associated with the patho-
logic alterations of nerves (8). Total hy-
perglycemic exposure is perhaps the most
important risk covariate (5,7). This vari-
ety has been shown to be stabilized, per-
haps even improved, by rigorous
glycemic control. This polyneuropathy
has been shown to be statistically associ-
ated with retinopathy and nephropathy
(1,6). Autonomic dysfunction and neuro-
pathic pain may develop over time.
The atypical DPNs are different from
DSPN in several important features, i.e.,
onset, course, manifestations, associa-
tions, and perhaps putative mechanisms
(3,4,9). They appear to be intercurrent
varieties, developing at any time during
the course of a patient’s diabetes (3,9).
Onset of symptoms may be acute, sub-
acute, or chronic, but the course is usually
monophasic or fluctuating over time. Pain
and autonomic symptoms are typical fea-
tures (3,9) and altered immunity has been
suggested. Studies have suggested that
impaired fasting glucose or impaired glu-
cose tolerance (IGT) is more common in
chronic idiopathic axonal polyneurop-
athy, but other studies do not support this
view (3,10).
Diabetic sensorimotor polyneuropathy
Case definition. The 1988 San Antonio
Conference on Diabetic Neuropathy (11),
Boulton et al. (4), and the American Acad-
emy of Neurology (AAN), American As-
sociation of Electrodiagnostic Medicine
(AAEM), and American Academy of Phys-
ical Medicine and Rehabi l i tat ion
(AAPM&R) (12) have proposed criteria
for diabetic neuropathies.
We propose separate definitions for
typical DPN (DSPN) and atypical DPNs.
DSPN is a symmetrical, length-dependent
sensorimotor polyneuropathy attributable
to metabolic and microvessel alterations
as a result of chronic hyperglycemia ex-
posure (diabetes) and cardiovascular risk
covariates. An abnormality of nerve con-
duction tests, which is frequently subclin-
ical, appears to be the first objective
quantitative indication of the condition.
The occurrences of diabetic retinopathy
and nephropathy in a given patient
strengthen the case that the polyneurop-
athy is attributable to diabetes. Other
causes of sensorimotor polyneuropathy
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need to be excluded. For epidemiologic
surveys or controlled clinical trials of
DSPN, we advocate the use of nerve con-
duction (NC) testing as an early and reli-
able indicator of the occurrence of this
neuropathy. To be reliable the test must
be done rigorously using appropriate ref-
erence values corrected for applicable
variables. Volunteered or elicited symp-
toms and signs and other clinical neuro-
physiologic abnormalities are also needed
to characterize the symptoms, signs, and
overall severity of the polyneuropathy.
Recent studies emphasize the importance
of the proficiency of the clinical neuro-
logic assessment (13,14). Atypical DPNs
have been less well characterized and
studied.
Estimating severity. Estimating the se-
verity of DSPN has not received the atten-
tion it deserves. For a given patient with
diabetes, it is not sufficient to simply
identify patients as having or not having
DSPN—severity also needs to be ascer-
tained. We suggest a reliable objective
and quantitative measure (i.e., NC abnor-
mality) as the minimal criteria for the di-
agnosis of DSPN. When NC values have
not been assessed, it is not possible to pro-
vide a confirmed diagnosis of DSPN—
only a possible or probable diagnosis.
Since the severity of DSPN is a combina-
tion of neuropathy symptoms, signs, neu-
rophysiologic test abnormalities, and
other dysfunctions and impairments, the
sum scores of various measures of neuro-
logic signs, symptoms, neurophysiologic
test abnormalities, or scores of function of
activities of daily living may provide an
indication of the severity (13).
An alternative approach to estimating
severity is to indicate severity by grades.
Dyck (15) described the stages of severity:
● Grade 0  no abnormality of NC, e.g.,
 5 NC normal deviates95th percen-
tile or another suitable NC criterion
● Grade 1a abnormality of NC, e.g., 
5 NC normal deviates95th percentile
without symptoms or signs
● Grade 1bNC abnormality of stage 1a
plus neurologic signs typical of DSPN
but without neuropathy symptoms
● Grade 2aNC abnormality of stage 1a
with or without signs (but if present,
2b) and with typical neuropathic
symptoms
● Grade 2b  NC abnormality of stage
1a, a moderate degree of weakness (i.e.,
50%) of ankle dorsiflexion with or
without neuropathy symptoms.
Definitions of minimal criteria for
typical DPN
1. Possible DSPN. The presence of
symptoms or signs of DSPN may include
the following: symptoms–decreased sen-
sation, positive neuropathic sensory
symptoms (e.g., “asleep numbness,”
prickling or stabbing, burning or aching
pain) predominantly in the toes, feet, or
legs; or signs–symmetric decrease of dis-
tal sensation or unequivocally decreased
or absent ankle reflexes.
2. Probable DSPN. The presence of a
combination of symptoms and signs of
neuropathy include any two or more of
the following: neuropathic symptoms,
decreased distal sensation, or unequivo-
cally decreased or absent ankle reflexes.
3. Confirmed DSPN. The presence of an
abnormality of NC and a symptom or
symptoms or a sign or signs of neuropa-
thy confirm DSPN. If NC is normal, a val-
idated measure of small fiber neuropathy
(SFN) (with class 1 evidence) may be
used.
To assess for the severity of DSPN,
several approaches can be recommended:
the graded approach outlined above, var-
ious continuous measures of sum scores
of neurologic signs, symptoms or nerve
test scores, scores of function of acts of
daily living or of predetermined tasks or
of disability. Irrespective of which ap-
proach is used, it is necessary to ensure
good performance of evaluations with
monitoring proficiency.
4. Subclinical DSPN. The presence of
no signs or symptoms of neuropathy are
confirmed with abnormal NCs or a vali-
dated measure of SFN (with class 1
evidence).
We recommend that definitions 1, 2,
or 3 be used for clinical practice and def-
initions 3 or 4 be used for research
studies.
Atypical DPNs
Before further classification of these poly-
neuropathies, setting the minimal criteria
for diagnosis and estimating severity and
further characterizing of epidemiologic
and mechanistic studies are needed. The
issue of painful, autonomic, and nerve
morphologic abnormalities are discussed
in subsequent sections.
PAINFUL DPN— A definition of pe-
ripheral neuropathic pain (NP) in diabe-
tes, adapted from a definition recently
proposed by the International Association
for the Study of Pain (16), is “pain arising
as a direct consequence of abnormalities
in the peripheral somatosensory system in
people with diabetes.” The prevalence of
NP in the diabetic population is difficult
to estimate as definitions have varied
enormously among studies; however, it is
crudely estimated that between 3 and
25% of patients might experience NP
(17). Similarly, there are limited data on
the natural history of painful DPN with
some studies suggesting that painful
symptoms improve with the worsening of
the sensory loss and others reporting no
appreciable occurrence of remissions
(17).
In practice, the diagnosis of painful
DPN is a clinical one, which relies on the
patient’s description of pain. The symp-
toms are distal, symmetrical, often associ-
ated with nocturnal exacerbations, and
commonly described as prickling, deep
aching, sharp, like an electric shock, and
burning (13) with hyperalgesia and fre-
quently allodynia upon examination (17).
The symptoms are usually associated with
the clinical signs of peripheral neuropa-
thy, although occasionally in acute pain-
ful DPN, the symptoms may occur in the
absence of signs. A number of simple nu-
meric rating scales can be used to assess
the frequency and severity of painful
symptoms (18), and other causes of NP
must be excluded. The severity of pain
can be reliably assessed by the visual an-
alog scale, which is the oldest and best
validated measure, or the numerical rat-
ing scale, e.g., the 11-point Likert scale
(0 no pain, 10 worst possible pain),
which has been most widely used in neu-
ropathic pain studies. A number of vali-
dated scales and questionnaires including
the Neuropathic Pain Symptoms Inven-
tory, Brief Pain Inventory, Neuropathic
Pain Questionnaire, and McGill Pain
Questionnaire, may be used (18). Quality
of life (QoL) improvement should also be
assessed, preferably using a validated
neuropathy-specific scale such as Neuro-
Qol or the Norfolk Quality of Life Scale
(19). Outcomes must be measured using
patient-reported improvement in scales
for pain and QoL as measured on vali-
dated instruments. External observers
can play no part in the assessment of the
subjects’ responses to new therapies for
NP; thus, measures such as the “physi-
cian’s global impression of response” are
not valid.
For clinical trials of putative new
therapies for painful DPN, rigorous pa-
tient selection with the use of NP scales
and outcome measures are indicated. In-
clusion criteria for such trials would nor-
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mally include NP associated with DPN for
6 months duration, mean weekly pain
score of between 4 and 10 on an 11-point
numerical rating scale, exclusion of pain
not associated with DPN, mononeuropa-
thies or proximal neuropathies, non-
neuropathic chronic pain, and central
pain.
Pharmacological management of
painful DPN almost exclusively consists
of symptomatic therapies (those that im-
prove symptoms of painful DPN without
an effect on underlying causes or natural
history) (20). The antioxidant -lipoic
acid administered intravenously is the
only pathogenetic treatment that has effi-
cacy confirmed from several randomized
controlled trials and confirmation in a
meta-analysis (level A evidence [12])
(21). Although spinal cord stimulation
might be useful in refractory painful DPN
(22), insufficient evidence exists for any
nonpharmacological therapies.
Level A evidence exists to support the
use of tricyclic antidepressants (e.g., am-
itriptyline), the anticonvulsants gabapen-
tin and pregabalin, and the serotonin and
norepinephrine reuptake inhibitor dulox-
etine (20,23–26). There is also random-
ized controlled trial (RCT) evidence for
the use of opiates such as oxycodone and
tramadol in painful DPN (20,23). There is
no evidence available to support the use
of the cannabinoids (27). Preliminary ev-
idence shows promise for topical treat-
ment using a 5% lignocaine plaster
applied to the most painful area (28),
although larger RCTs are required. First-
line therapies for painful DPN are a tricy-
c l i c an t idepres san t , du loxe t ine ,
pregabalin, or gabapentin, taking into ac-
count patient comorbidities and cost
(20,23). Combinations of first-line thera-
pies may be considered if there is pain,
despite a change in first-line mono-
therapy (20,23). If pain is still inade-
quately controlled, opiods such as
tramadol and oxycodone may be added in
a combination treatment (20,23). A num-
ber of areas relating to painful DPN war-
rant further investigation including
population-based prevalence and natural
history studies, trials using active com-
parators rather than placebo, assessment
of combination therapies in addition to
placebo, and longer-term studies of the
efficacy and durability of treatments of
painful DPN (23).
DIABETIC AUTONOMIC
NEUROPATHY— Diabetic auto-
nomic neuropathy (DAN) is a disorder of
the autonomic nervous system in the set-
ting of diabetes or metabolic derange-
ments of pre-diabetes after the exclusion
of other causes. DAN may affect cardio-
vascular, gastrointestinal (GI), and uro-
genital systems, and sudomotor function.
It may result in signs and symptoms or
may be subclinically detectable by spe-
cific tests.
Cardiovascular autonomic
neuropathy
Epidemiology. Cardiovascular auto-
nomic neuropathy (CAN) is defined as
the impairment of autonomic control of
the cardiovascular system. The preva-
lence of CAN varies widely from 2.5 to
50%. Factors that influence the preva-
lence of CAN include the diagnostic cri-
teria used, patient age, and the duration of
diabetes (29,30). Additional clinical cor-
relates and predictors of CAN include
glycemic control, presence of DPN, ne-
phropathy and retinopathy, blood pres-
sure (BP) levels, obesity, smoking, and
cholesterol and triglycerides levels
(30,31). Intervention studies have docu-
mented the protective effect of glycemic
control in type 1 diabetes (32) and a mul-
tifactorial strategy aimed at lifestyle
change with pharmacological correction
of hyperglycemia, hypertension, dyslipi-
demia, and microalbuminuria (33).
CAN is significantly associated with
overall mortality (34) and in some—but
not all—studies with morbidity such as
silent myocardial ischemia, coronary ar-
tery disease, stroke, diabetic nephropathy
progression, and perioperative morbid-
ity. Some pathogenetic mechanisms may
link CAN to cardiovascular dysfunction
and diabetic complications (34). Thus,
CAN assessment may be used for cardio-
vascular risk stratification in patients with
and without established cardiovascular
disease; as a marker for patients requiring
more intensive monitoring during the
perioperative period and other physiolog-
ical stresses; and as an indicator for more
intensive pharmacotherapeutic and life-
s t y l e management o f comorb id
conditions.
CAN assessment. Cardiovascular reflex
tests are the gold standard in clinical au-
tonomic testing. These tests have good
sensitivity, specificity, and reproducibil-
ity and are noninvasive, safe, well-
standardized, and easily performed (35).
However, a Valsalva maneuver must not
be performed in patients with prolifera-
tive retinopathy. The most widely used
tests assessing cardiac parasympathetic
function are based on the time-domain
heart rate (HR) response to deep breath-
ing, a Valsalva maneuver, and postural
change. Of these tests, HR to deep breath-
ing has the greatest specificity (80%).
Cardiovascular sympathetic function is
assessed by measuring the BP response to
orthostatic change and a Valsalva maneu-
ver. The performance of these tests should
be standardized, and the influence of con-
founding variables such as medications,
hydration, and antecedent activity should
be minimized. Age normative values
should be used. The combination of car-
diovascular autonomic tests with sudo-
motor function tests may allow a more
accurate diagnosis of DAN (36).
Diabetic patients with features of car-
diac autonomic dysfunction such as un-
explained tachycardia, orthostatic
hypotension, and poor exercise tolerance,
or with other symptoms of autonomic
dysfunction should be evaluated for the
presence of CAN. Screening for CAN
should be performed at the diagnosis
of type 2 diabetes and 5 years after
the diagnosis of type 1 diabetes, particu-
larly in patients at greater risk of CAN due
to a history of poor glycemic control,
cardiovascular risk factors, DPN, and
macro- and microangiopathic diabetic
complications.
Diagnostic criteria and staging of
CAN are still being debated. We suggest
that the presence of one abnormal cardio-
vagal test identifies possible or early CAN
(29); at least two abnormal HR tests are
required for a definite or confirmed diag-
nosis of CAN (30); and orthostatic hypo-
tension (asymptomatic or symptomatic),
in addition to HR test abnormalities, iden-
tify a condition of severe or advanced
CAN (31). Progressive stages of CAN are
associated with an increasingly worse
prognosis (34).
Assessment of potential consequences
of CAN. Attenuation (nondipping) or
loss of BP nocturnal fall (reverse dipping)
on ambulatory BP monitoring have been
associated with CAN and attributed to the
disruption of the circadian variation in
sympathovagal activity (37). In diabetic
patients, nondipping or reverse dipping
are independent predictors of cardiovas-
cular events and the progression of dia-
betic nephropathy. Ambulatory BP
monitoring may be useful in patients with
CAN to detect nondipping and to address
24-h BP control (Table 1).
QT prolongation is an independent
predictor of mortality in diabetic patients
and is weakly associated with CAN (38)
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(Table 1). The pathogenesis of QT pro-
longation is multifactorial and correlates
include female sex, nephropathy, coro-
nary heart disease, glycemic control, sys-
tolic BP, physical activity, and BMI.
CAN testing for clinical trials and re-
search. The time-domain HR tests and
the BP response to postural change have
the reproducibility necessary for clinical
trials. These tests were used as end points
in the Diabetes Control and Complica-
tions Trial/Epidemiology of Diabetes In-
terventions and Complications Study
(DCCT/EDIC) and other clinical trials.
Frequency-domain indexes obtained
by applying spectral analysis to HR vari-
ability of short (5–7 min) and longer
(24-h) electrocardiogram recordings pro-
vide a measure of sympathetic and para-
sympathetic modulation of HR. HR
spectral power in the high-frequency re-
gion is a measure of parasympathetic
modulation, while spectral power in the
low-frequency region provides a measure
of both sympathetic and parasympathetic
modulation. The low-frequency BP vari-
ability may provide a measure of sympa-
thetic modulation. To correctly assess the
significance of the different regions, res-
piration should be measured or con-
trolled breathing performed. These
methods, which need standardization,
have been widely used in research and as
end points in clinical trials.
Sympathetic outflow, at rest and in
response to various physiological pertur-
bations, can be measured directly via mi-
croelectrodes inserted into a fascicle of a
distal sympathetic nerve to the skin or
muscle. The technique is invasive and
time-consuming. Whole-body sympa-
thetic activity is most accurately assessed
by measurements of plasma concentra-
tions of noradrenaline and adrenaline.
Assessment of cardiac vagal barore-
flex sensitivity (BRS) combines informa-
tion derived from both HR and BP in
response to pharmacological or spontane-
ous BP perturbations. Cardiac vagal BRS
is a well-established prognostic index in
the general and diabetic populations (39)
and is frequently used in research studies
(Table 1). Cardiac sympathetic BRS can
be measured with simultaneous record-
ings of muscle sympathetic nerve activity.
Scintigraphic studies with radio la-
beled noradrenaline analogues allow
a direct semi-quantitative ([123I]-
metaiodobenzylguanidine [MIBG] and
single photon emission computed tomog-
raphy) and quantitative assessment
([11C]-hydroxyephedrine [HED] and
positron emission tomography) of cardiac
sympathetic integrity. Scintigraphic ab-
normalities are associated with CAN but
may also be present in patients with nor-
mal cardiovascular autonomic tests (40).
No standardized methodology or norma-
tive values exist, and available data on re-
producibility are limited. Scintigraphic
studies are appropriate to explore the ef-
fects of sympathetic dysfunction on car-
diac metabolism and function and are
useful in assessing cardiac sympathetic
function in research studies.
Issues for future research. Research is-
sues include: 1) the need for multivariate
longitudinal studies to clarify the natural
history of CAN in diabetes and pre-
diabetes, to evaluate the impact of phar-
macologic and lifestyle interventions
targeting CAN, and to determine the ef-
fect of CAN on clinical outcomes; 2) the
refinement and standardization of re-
search measures to permit more wide-
spread use; and 3) the need for studies of
combined cardiovascular autonomic and
other autonomic measures to improve di-
agnosis and outcome assessment.
GI autonomic neuropathy
GI motor, sensory, and secretory func-
tions are modulated by the interaction of
the autonomic (sympathetic and para-
sympathetic) and enteric nervous systems
with underlying rhythmicity generated by
the interstitial cells of Cajal located within
the smooth muscle. Evaluation of GI au-
tonomic function is difficult in humans,
and the diagnosis of GI autonomic neu-
ropathy is often one of exclusion. While
irreversible autonomic neuropathy has
been regarded as the cause of disordered
gut motility in diabetes, recent evidence
indicates a heterogeneous picture with a
range of fixed pathology and reversible
functional abnormalities (41). Acute hy-
perglycemia slows gastric emptying (GE),
while insulin-induced hypoglycemia ac-
celerates it.
Clinical features. Disordered GI motil-
ity may be associated with GI symptoms,
impaired oral drug absorption, poor gly-
cemic control, malnutrition, abnormal
postprandial regulation of BP, poor QoL,
and a high rate of hospitalization. The re-
Table 1—Cardiovascular autonomic tests and suggested indications for their use
Clinical diagnosis Research End point in clinical trials
HR cardiovascular tests Yes Yes Yes
Orthostatic hypotension test Yes Yes No (low sensitivity)
QT interval Yes (additional information and risk
stratification)
Yes No (low sensitivity)
ABPM for dipping status Yes (risk stratification) Yes No (low sensitivity)
HRV time- and frequency-
domain indices
Yes (early additional information
and risk stratification)
Yes Yes
BRS measures No (offers early additional
information and risk stratification
but low availability)
Yes Yes
Scintigraphic studies No (low availability and limited
standardization)
Yes Yes
MNSA No (low availability and limited
data in CAN)
Yes Possible (used in lifestyle intervention
trials in obesity)
Catecholamine assessment No (low availability) Yes Possible (used in lifestyle intervention
trials in obesity)
ABPM, ambulatory BP monitoring; HRV, heart rate variability; MNSA, muscle sympathetic nerve activity.
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lationships with symptoms and CAN are
relatively weak (42). Esophageal transit is
delayed in 50% of patients with long-
standing diabetes and may be associated
with regurgitation, dysphagia, and a pro-
pensity for pill-induced esophageal ero-
sions and strictures. Gastroparesis affects
40% of patients with longstanding dia-
betes. Symptoms are variable and more
common in patients with worse chronic
glycemic control and psychological
disorders (43).
The rate of GE is a major determi-
nant of postprandial blood glucose
changes. In insulin-treated patients, nu-
trient delivery needs to be matched to
the action of the exogenous insulin, and
delayed GE is a cause of otherwise un-
explained hypoglycemia (44).
Postprandial hypotension occurs fre-
quently in diabetes, and its magnitude is
related directly to GE rate. The prevalence
of disordered small and large intestinal
and anorectal motility is high. Diarrhea
may result from rapid or slow transit,
which is complicated by bacterial over-
growth and/or disordered secretion. Con-
stipation frequently occurs. Fecal
incontinence is not uncommon and is re-
lated to reduced and unstable internal
anal sphincter tone and impaired rectal
compliance and sensation.
Assessment. Studies of GI autonomic
neuropathy, whether performed for clin-
ical, epidemiological, or research pur-
poses, may potentially be focused on GI
symptoms, QoL, GI motility/transit, gly-
cemic control, and/or postprandial BP. A
number of instruments are available to
quantify GI symptoms, including the Di-
abetes Bowel Symptom Questionnaire.
Objective GE measurement is advocated
for the diagnosis of gastroparesis. Evalua-
tion of solid emptying is probably more
sensitive than that of low-nutrient liquid
or semi-solid meals. Medications that may
influence GE should ideally be with-
drawn, glycemia should ideally be 10
mmol/l throughout the test, and other
causes of gastroparesis must be excluded.
Failure to demonstrate delayed GE does
not necessarily imply that symptoms are
not due to “diabetic gastropathy,” but it
does help guide drug therapy. Scintigra-
phy is still regarded as the gold standard
technique for GE measurement. Stan-
dardization of the meal technique has
been improved by the recommendation
of a low-fat, egg white meal labeled with
technetium-99 (99mTc) sulfur colloid
(45). Breath tests using nonradioactive 13
C-acetate or -octanoic acid as a label are
appealing options, at least as a screening
tool. They are safe, easy to perform, inex-
pensive, and correlate well with scintigra-
phy. Ultrasonography (two-dimensional
and three-dimensional) is noninvasive
and two-dimensional ultrasound has
been validated for measuring emptying of
liquids and semi-solids. However, obesity
and abdominal gas, together with the ne-
cessity for an experienced operator, have
limited its widespread use. Surface elec-
trogastrography, used to detect abdomi-
nal gastric slow-wave activity, should be
regarded as a research tool. A barium
meal has no role in quantifying GE.
In the investigation of “diabetic diar-
rhea” celiac disease, exocrine pancreatic
insufficiency and small intestinal bacterial
overgrowth must be excluded. Tests of
anorectal motor and sensory function are
well developed for clinical use.
Erectile dysfunction
The prevalence of erectile dysfunction
(ED) among diabetic men varies from 35
to 90%, depending mainly on the various
methods applied (46). Neuropathy is one
of the leading causes of ED, along with
glycation of elastic fibers, peripheral vas-
culopathy, endothelial dysfunction, psy-
chological factors, drugs, and hormonal
changes (47). ED seems to be associated
with a higher rate of abnormal sensory
and autonomic tests. ED is a predictor of
cardiovascular events and is associated
with silent myocardial ischemia in type 2
diabetes (48). Alteration of QoL and de-
pressive symptoms seem to precede ED.
In clinical trials, ED was more severe and
more resistant to treatment in diabetic
than in nondiabetic individuals.
Key diagnostic procedures of ED in-
clude comprehensive patient history (sex-
ual, medical, drugs, alcohol, tobacco, and
psychosocial). The use of validated ques-
tionnaires, such as the International In-
dex of Erectile Function and the Sexual
Encounter Profile, is the most appropriate
method to characterize the frequency and
severity of ED symptoms. Other explora-
tions, including evaluation of nocturnal
penile tumescence, penile Doppler ultra-
sound, sacral response, bulbo-cavernosus
reflex, dorsal sensory nerve conduction of
the penis, amplitude and latency of penile
sympathetic skin response, and pudendal
nerve somatosensory-evoked potentials
(49), may be useful in patients who do not
respond to phosphodiesterase (PDE)-5
inhibitors. Due to the potential risks of
adverse or unanticipated drug interac-
tions, cardiac risk factors should be
evaluated and managed in all patients
with ED and cardiovascular disease. Al-
though ED is a part of autonomic dys-
function, ED prevalence in patients with
DAN and the prevalence of DAN among
patients with ED have not been analyzed
in large epidemiological studies.
Bladder dysfunction
Bladder complications can be due to an
alteration of the detrusor smooth muscle,
neuronal dysfunction, and urothelial dys-
function. Estimates of the prevalence of
bladder dysfunction are 43 to 87% of type
1 diabetic patients and 25% of type 2
diabetic patients. Diabetes duration is
significantly associated with severe incon-
tinence. The correlation between diabetic
cystopathy and peripheral neuropathy
ranges from 75 to 100%.
Common symptoms include dysuria,
frequency, urgency, nocturia, and incom-
plete bladder emptying. Other symptoms
include infrequent voiding, poor stream,
hesitancy in initiating micturition, recur-
rent cystitis, and stress and urgency uri-
nary incontinence. Since urological
conditions such as benign prostatic hy-
pertrophy in men or gynecological disor-
ders in women may share the same
symptoms, these causes must be excluded
by appropriate testing.
Diagnosis should use a validated
questionnaire for lower urinary tract
symptoms (LUTS). The type of bladder
dysfunction is most readily characterized
with complete urodynamic testing. Mea-
surement of peak urinary flow rate and
postvoid residual volume (PVR) should
be considered in diabetic patients with
LUTS when diagnosis remains doubtful
(50). PVR is ideally measured by portable
ultrasound (51). Urodynamic findings in-
clude impaired bladder sensation, in-
creased cystometric capacity, decreased
(or sometimes unexplained increased)
detrusor contractility, and increased PVR
(52). Microscopic urinalysis and culture
are essential in assessing patients com-
plaining of LUTS. Bladder dysfunction
has not been assessed up to now in epide-
miological and longitudinal studies or in
RCTs.
Sudomotor dysfunction
Sweat glands are innervated by the sudo-
motor, postganglionic, unmyelinated
cholinergic sympathetic C-fibers. Sudo-
motor dysfunction may result in dryness
of foot skin and has been associated with
foot ulceration (53). Assessment of sudo-
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motor dysfunction contributes to the de-
tection of autonomic dysfunction in DPN.
The quantitative sudomotor axon re-
flex test (QSART) is capable of detecting
distal small fiber polyneuropathy with a
sensitivity of75% (54). QSART may be
considered the reference method for the
detection of sudomotor dysfunction and
is used for clinical and research purposes.
Other available techniques for assessment
of sudomotor function include the ther-
moregulatory sweat test, silastic imprint
method, the indicator plaster method
(55), and the quantitative direct and indi-
rect reflex test (QDIRT) (56). Compara-
tive studies of the sensitivity and
specificity of these diagnostic techniques
are necessary. Sudomotor function has
not yet been assessed in epidemiological
and longitudinal studies or in RCTs.
EMERGING MARKERS OF
DPN: FOCUS ON SMALL
FIBERS— It was proposed earlier in
this article that if NC is normal, a vali-
dated measure (with class 1 evidence) of
SFN may be used. We have therefore as-
sessed the validity of established and
emerging measures of SFN and propose a
definition.
Nerve biopsy
Nerve biopsy detects unmyelinated fiber
damage while myelinated nerve fiber
morphology is still normal in patients
with early DPN (57). However, nerve bi-
opsy is an invasive and highly specialized
procedure that requires electron-
microscopy and cannot be advocated for
routine use.
Skin biopsy
Skin punch biopsy, a minimally invasive
procedure, allows morphometric quanti-
fication of intraepidermal nerve fibers
(IENF) most commonly expressed as the
number of IENF per length of section
(IENF/mm). Intra- and inter-observer
variability for the assessment of IENF
density is good, declines with age, is lower
in males than in females, and is not influ-
enced by weight or height (58). The blis-
ter technique is a less invasive procedure
that assesses innervation of the epidermis
alone and shows good agreement with
punch biopsy (58).
Diagnostic yield of IENF quantifica-
tion. No study assessing sensitivity and
specificity in DPN alone is available.
However, several studies in SFN, which
included patients with DPN, have been
published. In a study of 58 patients with
pure SFN (59), a cut-off IENF density of
8.8/mm at the ankle was associated
with a sensitivity of 77.2% and a specific-
ity of 79.6%. In a study of 210 patients
with SFN (60), which included 65 dia-
betic patients, the Z-scores and 5th per-
centile provided the highest specificity
(98 and 95%, respectively) but the lowest
sensitivity (31 and 35%, respectively)
compared with the receiver operating
characteristic analysis (specificity 64%,
sensitivity 78%). Thus, the diagnostic
yield of skin biopsy may depend on the
reference and cut-off values selected and
the definition of SFN. IENF density cor-
relates inversely with both cold and heat
detection thresholds (61).
The AAN, AAEM, and AAPM&R pro-
vide a level C recommendation for the use
of skin biopsy to diagnose DSPN, partic-
ularly SFN (36). The European Federa-
tion of the Neurological Societies and the
Peripheral Nerve Society revised guide-
lines on the use of skin biopsy in the di-
agnosis of SFN and have concluded that
IENF density is a reliable and efficient
technique to confirm the clinical diagno-
sis of SFN with a level A recommendation
(58). The presence of diffuse IENF swell-
ings, especially if large, may predict a de-
cline in IENF density (58)
DPN. IENF density is significantly re-
duced in patients with normal NC, sug-
gesting early damage to small nerve fibers
(62,63), and there is an inverse correla-
tion with the Neurological Disability
Score (63). Additionally, IENF density is
lower in diabetic patients with painful—
compared with painless—early neuropa-
thy (64). A 1-year diet and exercise
intervention program for patients with
SFN and IGT led to increased IENF den-
sity (65). These data suggest that IENF
loss is an early feature of diabetes,
progresses with increasing neuropathic
severity, and may repair with early
intervention.
Sudomotor innervations. Recently, a
skin biopsy study has shown a correlation
between sweat gland nerve fiber density,
neuropathic symptoms, neurological def-
icits, and sweat production in diabetic
patients (66).
Corneal confocal microscopy
Corneal confocal microscopy is a nonin-
vasive technique that can detect small
sensory corneal nerve fiber loss in diabetic
neuropathy (63), idiopathic SFN, and
Fabry disease. Corneal nerve fiber dam-
age correlates with IENF loss and the se-
verity of neuropathy in diabetic patients
(63), was more prominent in painful neu-
ropathy (63), and improved 6 months
after combined pancreas/kidney trans-
plantation (67). Its quantification may
be a surrogate marker of diabetic
neuropathy.
Nerve axon reflex/flare response
Stimulation of C-nociceptive fibers by
acetylcholine iontophoresis induces vaso-
dilation, which can be quantitatively mea-
sured and serve as a measure of small fiber
function (68). This technique correlates
with other measurements of small fiber
function and may be considered for the
diagnosis of SFN in diabetic patients. The
laser Doppler imaging flare test evaluates
44°C heat-induced vasodilation and is re-
duced in subjects with IGT and type 2
diabetic patients with and without neu-
ropathy (69). Further studies are required
to validate these tests as diagnostic tools
or as outcome measures in clinical trials.
Definition of SFN
In diabetic patients, we propose to grade
SFN as follows: 1) possible: the presence
of length-dependent symptoms and/or
clinical signs of small fiber damage; 2)
probable: the presence of length-
dependent symptoms, clinical signs of
small fiber damage, and normal sural NC
study; and 3) definite: the presence of
length-dependent symptoms, clinical
signs of small fiber damage, normal sural
NC study, and altered IENF density at the
ankle and/or abnormal quantitative sen-
sory testing thermal thresholds at the foot.
At present, it is not possible to suggest
criteria to define the severity of SFN in
DPN.
CONCLUSIONS— Diabetic poly-
neuropathy is one of the most common
long-term complications of diabetes af-
fecting50% of all diabetic people. This
review by an international panel of ex-
perts examines recent literature regarding
diagnostic criteria for DPN, painful DPN,
and autonomic neuropathy and makes di-
agnostic recommendations in the context
of clinical practice and research. The re-
view also discusses emerging markers of
DPN. Finally, the diagnostic criteria for
DPN are likely to evolve with develop-
ments in the field, and there is clearly a
need for experts in the field to provide
periodic updates.
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